Amputation risks re-assessed for ‘cardioprotective’ SGLT2 inhibitors

New analysis of pooled data has provided more reassurance that the SGLT2 inhibitor canagliflozin is not associated with a higher risk of limb amputations, Australian researchers say. The concern about amputation risk was raised years ago in CANVAS trial findings – and reported here in the limbic – but has not been reproduced in subsequent ...

Already a member?

Login to keep reading.

© 2021 the limbic